92 related articles for article (PubMed ID: 30653304)
1. CRIF1-CDK2 Interface Inhibitors: An Unprecedented Strategy for Modulation of Cell Radiosensitivity.
Ran Q; Xiang Y; Stephen P; Wu C; Li T; Lin SX; Li Z
J Am Chem Soc; 2019 Jan; 141(4):1420-1424. PubMed ID: 30653304
[TBL] [Abstract][Full Text] [Related]
2. CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma.
Ran Q; Jin F; Xiang Y; Xiang L; Wang Q; Li F; Chen L; Zhang Y; Wu C; Zhou L; Xiao Y; Chen L; Wu J; Zhong JF; Li SC; Li Z
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20511-20516. PubMed ID: 31548420
[TBL] [Abstract][Full Text] [Related]
3. CRIF1 interacting with CDK2 regulates bone marrow microenvironment-induced G0/G1 arrest of leukemia cells.
Ran Q; Hao P; Xiao Y; Xiang L; Ye X; Deng X; Zhao J; Li Z
PLoS One; 2014; 9(2):e85328. PubMed ID: 24520316
[TBL] [Abstract][Full Text] [Related]
4. CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer.
Sang X; Belmessabih N; Wang R; Stephen P; Lin SX
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205737
[TBL] [Abstract][Full Text] [Related]
5. CR6-interacting factor 1 interacts with Gadd45 family proteins and modulates the cell cycle.
Chung HK; Yi YW; Jung NC; Kim D; Suh JM; Kim H; Park KC; Song JH; Kim DW; Hwang ES; Yoon SH; Bae YS; Kim JM; Bae I; Shong M
J Biol Chem; 2003 Jul; 278(30):28079-88. PubMed ID: 12716909
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte-specific protein tyrosine kinase (Lck) interacts with CR6-interacting factor 1 (CRIF1) in mitochondria to repress oxidative phosphorylation.
Vahedi S; Chueh FY; Chandran B; Yu CL
BMC Cancer; 2015 Jul; 15():551. PubMed ID: 26210498
[TBL] [Abstract][Full Text] [Related]
7. Multifunctions of CRIF1 in cancers and mitochondrial dysfunction.
Jiang Y; Xiang Y; Lin C; Zhang W; Yang Z; Xiang L; Xiao Y; Chen L; Ran Q; Li Z
Front Oncol; 2022; 12():1009948. PubMed ID: 36263222
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
9. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity.
Calbó J; Serna C; Garriga J; Graña X; Mazo A
Cell Death Differ; 2004 Oct; 11(10):1055-65. PubMed ID: 15309028
[TBL] [Abstract][Full Text] [Related]
10. CR6-interacting factor 1 represses the transactivation of androgen receptor by direct interaction.
Suh JH; Shong M; Choi HS; Lee K
Mol Endocrinol; 2008 Jan; 22(1):33-46. PubMed ID: 17885209
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel nonpeptide allosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays.
Hu Y; Li S; Liu F; Geng L; Shu X; Zhang J
Bioorg Med Chem Lett; 2015 Oct; 25(19):4069-73. PubMed ID: 26316466
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Cyclin A2 Binding Site and Nanomolar Inhibitors of Cyclin A2-CDK2 Complex.
Kim SS; Alves MJ; Gygli P; Otero J; Lindert S
Curr Comput Aided Drug Des; 2021; 17(1):57-68. PubMed ID: 31889491
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
14. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
15. CR6-interacting factor 1 interacts with orphan nuclear receptor Nur77 and inhibits its transactivation.
Park KC; Song KH; Chung HK; Kim H; Kim DW; Song JH; Hwang ES; Jung HS; Park SH; Bae I; Lee IK; Choi HS; Shong M
Mol Endocrinol; 2005 Jan; 19(1):12-24. PubMed ID: 15459248
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
17. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
[TBL] [Abstract][Full Text] [Related]
18. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations.
Raju U; Nakata E; Yang P; Newman RA; Ang KK; Milas L
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):886-94. PubMed ID: 12377342
[TBL] [Abstract][Full Text] [Related]
19. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
[TBL] [Abstract][Full Text] [Related]
20. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Cai D; Byth KF; Shapiro GI
Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
